Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-01-16
2007-01-16
Wehbé, Anne M. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S455000, C435S456000
Reexamination Certificate
active
09080935
ABSTRACT:
A variety of genetic constructs are disclosed that will find both in vitro and in vivo use in the area of tumor biology and cancer therapy. In particular, expression constructs are provided that contain a p16 encoding region and other regulatory elements necessary for the expression of a p16 transcript. One version of the expression construct is a replication-deficient adenoviral vector. Also provided are methods for the transformation of cell lines and the inhibition of cancer cell proliferation.
REFERENCES:
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5624819 (1997-04-01), Skolnick et al.
patent: 5672508 (1997-09-01), Gyuris et al.
patent: 5739027 (1998-04-01), Kamb
patent: 5747469 (1998-05-01), Roth et al.
patent: 5801236 (1998-09-01), Kamb
patent: 6251871 (2001-06-01), Jin et al.
patent: 0273085 (1988-07-01), None
patent: WO 94/09135 (1994-04-01), None
patent: 9428152 (1994-12-01), None
patent: WO 95/25429 (1995-09-01), None
patent: WO 95/25813 (1995-09-01), None
patent: WO 95/28169 (1995-10-01), None
patent: WO 95/28483 (1995-10-01), None
patent: WO 95/30002 (1995-11-01), None
patent: WO 96/25507 (1996-08-01), None
patent: WO 98/35554 (1998-08-01), None
US 5,691,198, 11/1997, Jin et al. (withdrawn)
Vogelstein et al. (1993) Trends in Genetics, vol. 9 (4), 238-241.
Gura (1997) Science, vol. 278, 1041-1042, Nov. 1997.
Adreansky (1996) Proc. Natl. Acad. Sci., vol. 93, 11313-11318.
Vieweg et al. (1995) Cancer Invest., vol. 13 (2), 193-201.
Verma et al. (1997) Science, vol. 289, 239-242.
Marshall (1995) Science, vol. 269, 1050-1055.
Orkin et al. (1995) “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”.
Harrington et al. (2001) J. Urol., vol. 166, 1220-1233.
Robbins et al. (1998) Pharmacol. ther., vol. 80, 35-47.
Rainov et al. (2001) Curr. Gen. Ther., vol. 1, 367-383.
Arap et al., “Replacement of the p16/CDKN2 Gene Suppresses Human Glioma Cell Growth,”Cancer Research, 55:1351-1354, Mar. 1995.
Baichwal and Sugden, “Vectors For Gene Transfer Derived From Animal DNA Viruses: Transient and Stable Expression of Transferred Genes,”In: Gene Transfer, R. Kucherlapati, ed., New York, Plenum Press, pp. 117-148, 1986.
Benevisty and Reshef, “Direct Introduction of Genes Into Rats and Expression of the Genes,”Proc. Natl. Acad. Sci. USA, 83:9551-9555, Dec. 1986.
Boshart et al., “A Very Strong Enhancer Is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus,”Cell, 41:521-530, Jun. 1995.
Caldas et al., “Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma,”Nature Genetics, 8:27-32, Sep. 1994.
Chang et al., “Foreign Gene Delivery and Expression in Hepatocytes Using a Hepatitis B Virus Vector,”Hepatology(Abstract), 42nd Annual Meeting of The American Association for the Study of Liver Diseases, Chicago, Illinois, 14(4)(Pt. 2):124A, Nov. 1991.
Cheng et al., “p16 Alterations and Deletion Mapping of 9p21-p22 in Malignant Mesothelioma,”Cancer Research, 54:5547-5551, Nov. 1994.
Culver et al., “In VivoGene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors,”Science, 256:1550-1552, Jun. 1992.
Dubensky et al., “Direct transfection of viral and plasmid DNA into the liver or spleen of mice,”Proc. Natl. Acad. Sci. USA, 81;7529-7533, Dec. 1984.
Fearon et al., “Identificatoin of a Chromosome 18q Gene That Is Altered in Colorectal Cancers,”Science, 247:49-56, Jan. 1990.
Friedmann, “Progress Toward Human Gene Therapy, ”Science, 244:1275-1281, Jun. 1989.
Fujiwara et al., “Therapeutic Effect of a Retroviral Wild-Type p53 Expression Vector in an Orthotopic Lung Cancer Model,”Journal of the National Cancer Institute, 86(19):1458-1462, Oct. 1994.
Ghosh and Bachhawat, “Targeting of Liposomes to Hepatocytes,”In: Liver Diseases, Targeted Diagnosis and Therapy Using Specific Receptors and Ligands, G. Wu, C. Wu ed., New York: Marcel Dekker, pp. 87-104, 1991.
Graham and Prevec, “Adenovirus-Based Expression Vectors and Recombinant Vaccines,”Biotechnology, 20:363-390, 1992.
Graham and Prevec, “Manipulation of Adenovirus Vectors,”In: Methods in Molecular Biology: Gene Transfer and Expression Protocol, E.J. Murray (ed.), Clifton, NJ: Humana Press, 7:109-128, 1991.
Gruis et al., “Genetic Evidence in Melanoma and Bladder Cancers that p16 and p53 Function in Separate Pathways of Tumor Suppression,”American Jounal of Pathology, 146(5):1199-1206, May 1995.
Grunhaus and Horwitz, “Adenoviruses as cloning vectors,”Virology, 3:237-252, 1992.
Grunicke and Maly, “Role of GTPases and GTPase Regulatory Proteins in Oncogenesis,”Critical Reviews in Oncogenesis, 4(4):389-402, 1993.
Harbour et al., “Abnormalities in Structure and Expression of the Human Retinoblastoma Gene in SCLC,”Science, 241:353-357, Jul. 1988.
Herman et al., “Abnormal DNA methylation frequently inactivates the putative tumor suppressor CKDN2/p16 in many tumor types,”Abstract, Proceedings of The American Association for Cancer Research, 36:201, Mar. 1995.
Herz and Gerard, “Adenovirus-mediatedtransfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice,”Proc. Natl. Acad. Sci. USA, 90:2812-2816, Apr. 1993.
Hesdorffer et al., “Efficient Gene Transfer in Live Mice Using a Unique Retroviral Packaging Line,”DNA and Cell Biology, 9(10):717-723, 1990.
Hussussian et al., “Germline p16 mutations in familial melanoma,”Nature Genetics, 8:15-21, Sep. 1994.
Kamb et al., “A Cell Cycle Regulator Poentially Involved in Genesis of Many Tumor Types,”Science, 264:436-440, Apr. 1994.
Kamb et al., “Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus,”Nature Genetics, 8:22-26, Apr. 1994.
Kamb et al., “Rates of p16 (MTS1) Mutations in Primary Tumors with 9p Loss,”Science, 265:415-417, Jul. 1994.
Kaneda et al., “Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat Liver,”Science, 243:375-378, Jan. 1989.
Le Gal La Salle et al., “An Adenovirus Vector for Gene Transfore into Neurons and Glia in the Brain,”Science, 259:988-990, Feb. 1993.
Levrero et al., “Defective and nondefective adenovirus vectors for expressing foreign genesin vitroandin vivo ,” Gene, 101:195-202, 1991.
Li et al., “Assessment of Recombinant Adenoviral Vectors for Hepatic Gene Therapy,”Human Gene Therapy, 4:403-409, 1993.
Markowitz et al., “A Safe Packaging Line for Gene Transfer: Separating Viral Genes on Two Different Plasmids,”Journal of Virology, 62(4):1120-1124, Apr. 1988.
Marx, “Learning How to Suppress Cancer,”Science, 261:1385-1387, Sep. 1993.
Mitsudomi et al., “p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features,”Oncogene, 7:171-180, 1992.
Mori et al., “Frequent Somatic Mutatio of theMTS1/CDK41(Multiple Tumor Suppressor/Cyclin-dependent Kinase 4 Inhibitor) Gene in Esophageal Squamous Cell Carcinoma,”Cancer Research, 54:3396-3397, Jul. 1994.
Mulligan, “The Basic Science of Gene Therapy,”Science, 260:926-932, May 1993.
Nicolau et al., Lipsomes as Carriers forin VivoGene Transfer and Expression,Methods in Enzymology, 149:157-176, 1987.
Nobori et al., “Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers,”Nature, 368:753-756, Apr. 1994.
Okamoto et al., “Mutations and altered expression of p16INK4in human cancer,”Proc. Natl. Acad. Sci. USA, 91:11045-11049, Nov. 1994.
Okamoto et al., “Mutations in the p16INK4/MTS1/CDKN2,p15INK4B/MTS2, and p18 Genes in Primary and Metastatic Lung Cancer,”Cancer Research
Jin Xiaomei
Roth Jack A.
Board of Regents , The University of Texas System
Fulbright & Jaworski L.L.P.
Wehbe Anne M.
LandOfFree
p16 expression constructs and their application in cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with p16 expression constructs and their application in cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and p16 expression constructs and their application in cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3722153